JP2013512966A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512966A5
JP2013512966A5 JP2012543237A JP2012543237A JP2013512966A5 JP 2013512966 A5 JP2013512966 A5 JP 2013512966A5 JP 2012543237 A JP2012543237 A JP 2012543237A JP 2012543237 A JP2012543237 A JP 2012543237A JP 2013512966 A5 JP2013512966 A5 JP 2013512966A5
Authority
JP
Japan
Prior art keywords
aminomethyl
methyl
acid
hexanoic acid
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012543237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512966A (ja
JP5815552B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/059426 external-priority patent/WO2011071995A2/en
Publication of JP2013512966A publication Critical patent/JP2013512966A/ja
Publication of JP2013512966A5 publication Critical patent/JP2013512966A5/ja
Application granted granted Critical
Publication of JP5815552B2 publication Critical patent/JP5815552B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012543237A 2009-12-08 2010-12-08 眼疾患を治療する化合物および方法 Expired - Fee Related JP5815552B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26764509P 2009-12-08 2009-12-08
US61/267,645 2009-12-08
PCT/US2010/059426 WO2011071995A2 (en) 2009-12-08 2010-12-08 Compounds and methods of treating ocular disorders

Publications (3)

Publication Number Publication Date
JP2013512966A JP2013512966A (ja) 2013-04-18
JP2013512966A5 true JP2013512966A5 (https=) 2014-01-30
JP5815552B2 JP5815552B2 (ja) 2015-11-17

Family

ID=44146158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012543237A Expired - Fee Related JP5815552B2 (ja) 2009-12-08 2010-12-08 眼疾患を治療する化合物および方法

Country Status (7)

Country Link
US (3) US8722669B2 (https=)
EP (1) EP2509596B1 (https=)
JP (1) JP5815552B2 (https=)
AU (1) AU2010328186B2 (https=)
CA (1) CA2783699C (https=)
ES (1) ES2758554T3 (https=)
WO (1) WO2011071995A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
RU2015120478A (ru) 2012-12-20 2017-01-25 Альдейра Терапьютикс, Инк. Пери-карбинолы
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
SG11201505599YA (en) 2013-01-25 2015-08-28 Aldeyra Therapeutics Inc Novel traps in the treatment of macular degeneration
WO2016085939A2 (en) * 2014-11-24 2016-06-02 Case Western Reserve University Compounds and methods of treating ocular disorders
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
MX2019010576A (es) 2017-03-16 2019-10-07 Aldeyra Therapeutics Inc Compuestos polimorficos y usos de los mismos.
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス, インコーポレイテッド 炎症性障害の処置
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3856478A4 (en) 2018-09-25 2022-06-08 Aldeyra Therapeutics, Inc. FORMULATIONS FOR THE TREATMENT OF DRY EYE
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
JP2020078649A (ja) * 2020-02-27 2020-05-28 キヤノン株式会社 眼科装置及びその制御方法、並びに、プログラム
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
US4826860A (en) 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
US5185351A (en) 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5597809A (en) 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
AU3704500A (en) 1999-02-19 2001-01-22 University Of Iowa Research Foundation, The Diagnostics and therapeutics for arterial wall disruptive disorders
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
ES2317839T3 (es) 1999-06-10 2009-05-01 Warner-Lambert Company Llc Acidos 3-propil gamma-aminobutiricos monosustituidos.
IL152770A0 (en) 2000-06-26 2003-06-24 Warner Lambert Co Gabapentin analogues for sleep disorders
BR0115783A (pt) 2000-11-30 2003-09-16 Pfizer Prod Inc Combinação de agonistas de gaba e inibidores de sorbitol desidrogenase
CA2442476A1 (en) 2001-03-30 2002-10-10 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
DE10206723A1 (de) 2002-02-18 2003-09-04 Ulrich Schraermeyer Therapie von Erkrankungen des Auges und des Zentralen Nervensystems
WO2004009072A2 (en) 2002-07-23 2004-01-29 The Regents Of The University Of Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
US7875270B2 (en) 2002-09-17 2011-01-25 Abbott Medical Optics Inc. Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
BR0315103A (pt) 2002-10-07 2005-08-16 Artesian Therapeutics Inc Compostos de diidropiridina tendo capacidade simultânea de bloquear os canais de cálcio do tipo l e inibir a atividade da fosfodiesterase do tipo 3
WO2004036182A2 (en) 2002-10-17 2004-04-29 Control Delivery Systems, Inc. Methods for monitoring treatment of disease
MXPA05006209A (es) 2002-12-13 2005-08-19 Warner Lambert Co Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados.
US20050031652A1 (en) 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
ITRM20030485A1 (it) 2003-10-22 2005-04-23 Tubilux Pharma S P A Composizione a base di citicolina in associazione con vitamine per la prevenzione ed il trattamento di patolgie oculari.
ES2234428B1 (es) 2003-12-09 2006-11-01 Universidad Miguel Hernandez Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugia fotorrefractiva.
MXPA06007076A (es) 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
CA2550540A1 (en) 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
US20050277698A1 (en) 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
AU2005210504B2 (en) 2004-01-30 2009-01-08 Merck Sharp & Dohme Corp. Crystalline polymorphs of a CXC-chemokine receptor ligand
EP1722766A2 (en) 2004-02-17 2006-11-22 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
WO2005079781A1 (en) 2004-02-25 2005-09-01 La Trobe University Therapeutic and/or prophylactic method
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
CA2565545A1 (en) 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
US8372814B2 (en) 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
BRPI0511396B1 (pt) 2004-06-18 2021-07-27 University Of Washington Uso de 9-cis-retinil éster e uso de um derivado de retinal sintético
SI1768657T1 (sl) 2004-06-23 2009-02-28 Sirion Terapeutics Inc Postopki in sestavki za zdravljenje oftalmičnih obolenj z derivati retinila
US20060110428A1 (en) 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
US20080033053A1 (en) 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
EP1776097A1 (en) 2004-07-26 2007-04-25 Allergan, Inc. Methods of treating ophthalmic conditions
WO2006015930A1 (en) 2004-08-10 2006-02-16 Nicox S.A. Phenol derivatives
JP2008518586A (ja) 2004-09-09 2008-06-05 ユニバーシティ オブ ワシントン オールトランスレチノールすなわちオールトランス13,14−ジヒドロレチノールサチュラーゼ及びその使用方法
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2006039327A2 (en) 2004-10-01 2006-04-13 Merck & Co., Inc. Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
BRPI0516308A2 (pt) 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
CN101065139A (zh) 2004-10-09 2007-10-31 扶瑞药业股份有限公司 眼用药剂递送系统
BRPI0516112A (pt) 2004-10-15 2008-08-26 Janssen Pharmaceutica Nv métodos para neuroproteção
US7351724B2 (en) 2004-10-15 2008-04-01 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
EP1814535A4 (en) 2004-11-08 2008-06-04 Nitromed Inc NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES
WO2006055526A2 (en) 2004-11-16 2006-05-26 Nu-Tein Co., Inc. Compositions useful to treat ocular neovascular diseases and macular degeneration
CA2638753A1 (en) 2004-12-08 2006-06-15 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
AR055831A1 (es) 2004-12-30 2007-09-12 Janssen Pharmaceutica Nv Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
US20060252107A1 (en) 2005-02-22 2006-11-09 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
US20080275134A1 (en) 2005-02-24 2008-11-06 University Of Washington Methods for Treatment of Retinal Degenerative Disease
PL1906916T3 (pl) 2005-05-10 2009-02-27 Alcon Inc Zawiesina do oczu obejmująca lek okulistyczny, poloksaminę i glikolowy środek regulujący toniczność, zastosowanie wymienionej kompozycji do wytwarzania leku do leczenia zaburzeń wzroku
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
US20070021500A1 (en) 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
KR20080031474A (ko) 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
EP1910385B1 (en) 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
WO2007047744A2 (en) 2005-10-14 2007-04-26 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US20070167527A1 (en) 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
EP2021502A4 (en) 2006-05-09 2010-08-25 Mas Metabolic Analytical Servi GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY
MX2008016167A (es) 2006-06-22 2009-02-10 Sirion Therapeutics Inc Metodos y composiciones para el tratamiento de condiciones oftalmicas via modulacion de actividad de megalina.
AU2007299920A1 (en) 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20080103103A1 (en) 2006-10-30 2008-05-01 Bahram Memarzadeh Reagents and methods to treat ocular diseases and infection
WO2008098027A2 (en) 2007-02-06 2008-08-14 Allergan, Inc. Treatment of ischemic retinal conditions with memantine
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
WO2008104861A1 (en) 2007-02-27 2008-09-04 Karine Berthet Method for the treatment of an individual having a vascular deficiency in the upper part of the body especially a cerebral vascular deficiency or an ocular vascular disorder
WO2009023411A1 (en) 2007-08-09 2009-02-19 Bausch & Lomb Incorporated Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases
WO2009023877A2 (en) 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions
EP2192916A4 (en) 2007-08-23 2012-04-04 Univ Leland Stanford Junior MODULATION OF SYNAPTOGENESIS
WO2009029762A2 (en) 2007-08-31 2009-03-05 President And Fellows Of Harvard College Farnesylamine inhibitors of the visual cycle
IL292561A (en) 2007-10-12 2022-06-01 Astellas Inst For Regenerative Medicine Improved methods of rpe cell production and rpe cell preparations
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
JP6022746B2 (ja) 2008-02-11 2016-11-09 ユニヴァーシティ オブ ワシントン 加齢関連性網膜機能不全の治療及び予防方法
CA2753844A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
US20140357611A1 (en) 2009-12-08 2014-12-04 Case Western Reserve University Compounds and methods of treating ocular disorders
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
WO2012098281A2 (es) 2011-01-19 2012-07-26 Universidad Miguel Hernández De Elche Péptidos moduladores de receptores trp y sus usos

Similar Documents

Publication Publication Date Title
JP2013512966A5 (https=)
CA2374755A1 (en) Mono- and disubstituted 3-propyl gamma-aminobutyric acids
JP2016508994A5 (https=)
JP2003502308A5 (https=)
HRP20190500T1 (hr) Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina
JP2023002544A5 (https=)
JP2009514874A5 (https=)
RU2015126016A (ru) Заболевания, связанные с токсичным альдегидом, и их лечение
JP2011051993A5 (https=)
US20140228446A1 (en) Organic compounds
KR20160093000A (ko) 창자 과투과성을 치료하기 위한 티로신 하이드록실라제 억제제
JP2013509411A5 (https=)
WO2019046287A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B
EP4034156A1 (en) Combination therapy with cgrp antagonists
US20050059654A1 (en) Method for treatment of depression and anxiety disorders by combination therapy
JP2017512211A5 (https=)
JP2005507387A5 (https=)
US20240398762A1 (en) Pharmaceutical composition with analgesic and/or antipruritic functions and application thereof
JP2011521992A (ja) アトルバスタチン4−(ニトロキシ)ブチルエステルおよび脂質低下剤を含む組成物
EP3340972A1 (en) Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
EP1820502A1 (en) Active substance combination comprising azolylcarbinol compounds
WO2006037061A3 (en) Compositions and methods of using d-dopa to treat parkinson's disease
CN102711797A (zh) 治疗主动脉纤维化的组合物及方法
US20210030701A1 (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
JP2003523993A5 (https=)